Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effets du HIIT sur le métabolisme osseux chez les personnes ayant subi un AVC chronique

17 septembre 2026 mis à jour par: The Hong Kong Polytechnic University

Effets de l'entraînement fractionné à haute intensité sur le métabolisme osseux chez les personnes ayant subi un AVC chronique : un essai contrôlé randomisé de validation de principe

Objectives: To investigate the effects of high-intensity interval training (HIIT) on musculoskeletal fitness in chronic stroke survivors.

Hypothesis to be tested: HIIT, performed on a recumbent stepper, will significantly enhance muscle power in chronic stroke survivors when compared with moderate-intensity continuous training (MICT) Design and subjects: Assessor-blinded, stratified, randomised, placebo-controlled clinical trial involving eligible 66 chronic stroke survivors.

Interventions: Participants will be randomly allocated to one of three groups: the HIIT group, the MICT group, or a stretching group (active control). Each group will attend sessions three times per week for 12 consecutive weeks, totaling 36 training sessions.

Main outcome measures: Assessments will be conducted at baseline, at mid-term of the intervention (week 6), at the end of the intervention (week 12), and at a 12-week follow-up (week 24). The primary outcome measure will be muscle power. Secondary outcome measures will include muscle strength, body composition, biomarkers, motor function, balance function, cardiorespiratory response, and psychosocial response.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

66

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

50 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion criteria:

  • Men and postmenopausal women aged 50-80 years
  • 1-5 years following the first-ever stroke confirmed by magnetic resonance imaging or computed tomography
  • Able to walk 10 meters independently with or without a walking aid
  • Class I or II according to the New York Heart Association Functional Classification (no limitation or slight limitation of physical activity due to symptoms during ordinary physical activity)

Exclusion criteria:

  • Presence of other neurological comorbidities, significant liver or renal diseases, thyroid or parathyroid diseases, rheumatoid arthritis, or a fracture within the past 6 months
  • Undergoing osteoporosis treatments within the past 3 years, use of oral corticosteroids for more than 3 months within the past year, or botulinum toxin injections in the paretic lower limb within the past 6 months
  • Participation in ongoing stroke rehabilitation services or structured exercise programme
  • Cognitive or communication issues that could limit the ability to follow instructions
  • Contraindications to HIIT, graded exercise testing, or failure to pass medical clearance from a specialist

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: High-intensity interval training

The HIIT session will consist of a 3-minute warm-up, a 20-minute main exercise, and a 2-minute cool-down. The main exercise for HIIT will include ten high-intensity intervals, interspersed with ten low-intensity intervals.

There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.

Comparateur actif: Moderate-intensity continuous training

The MICT session will consist of a 3-minute warm-up, a main exercise that approximately matches the total workload of the HIIT session (lasting about 30 minutes), and a 2-minute cool-down. The intensity during the main exercise for MICT will remain below the vigorous level by progressively adjusting the workload throughout the intervention period.

There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.

Comparateur actif: Stretching

The stretching group will receive 25 minutes of whole-body stretching.

There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change from Baseline in Muscle Power at Week 12
Délai: Baseline and Week 12

Muscle power (watt) of knee extensors on both the paretic and nonparetic sides will be measured using the isokinetic dynamometer.

Change=(Week 12 Level - Baseline Level)

Baseline and Week 12

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change from Baseline in Muscle Power at Week 24
Délai: Baseline and Week 24

Muscle power (watt) of knee extensors on both the paretic and nonparetic sides will be measured using the isokinetic dynamometer. Change=(Week 24 Level - Baseline Level)

Baseline and Week 24
Change from Baseline in Muscle Strength (Nm) at Week 12
Délai: Baseline and Week 12

Muscle strength (Nm) of knee extensors on both the paretic and nonparetic sides will be measured using the isokinetic dynamometer.

Change=(Week 12 Level - Baseline Level)

Baseline and Week 12
Change from Baseline in Muscle Strength (Nm) at Week 24
Délai: Baseline and Week 24

Muscle strength (Nm) of knee extensors on both the paretic and nonparetic sides will be measured using the isokinetic dynamometer.

Change=(Week 24 Level - Baseline Level)

Baseline and Week 24
Change from Baseline in Muscle Strength (kg) at Week 12
Délai: Baseline and Week 12

Handgrip strength (kg) on both sides will be measured using a handheld dynamometer.

Change=(Week 12 Level - Baseline Level)

Baseline and Week 12
Change from Baseline in Muscle Strength (kg) at Week 24
Délai: Baseline and Week 24

Handgrip strength (kg) on both sides will be measured using a handheld dynamometer.

Change=(Week 24 Level - Baseline Level)

Baseline and Week 24
Change from Baseline in Body Composition (kg) at Week 12
Délai: Baseline and Week 12

Whole-body skeletal muscle mass (kg), bone mineral content (kg), fat mass (kg), and segmental lean mass (kg) will be measured using bioelectrical impedance analysis (BIA).

Change=(Week 12 Level - Baseline Level)

Baseline and Week 12
Change from Baseline in Body Composition (kg) at Week 24
Délai: Baseline and Week 24

Whole-body skeletal muscle mass (kg), bone mineral content (kg), fat mass (kg), and segmental lean mass (kg) will be measured using bioelectrical impedance analysis (BIA).

Change=(Week 24 Level - Baseline Level)

Baseline and Week 24
Change from Baseline in Body Composition (%) at Week 12
Délai: Baseline and Week 12

Body fat percentage (%) will be measured using bioelectrical impedance analysis (BIA).

Change=(Week 12 Level - Baseline Level)

Baseline and Week 12
Change from Baseline in Body Composition (%) at Week 24
Délai: Baseline and Week 24

Body fat percentage (%) will be measured using bioelectrical impedance analysis (BIA).

Change=(Week 24 Level - Baseline Level)

Baseline and Week 24
Change from Baseline in Biomarkers at Week 12
Délai: Baseline and Week 12

Volume-corrected serum concentration (mg/dL) of myokines, bone markers, pro-inflammatory markers, biomarkers of oxidative stress will be measured using enzyme-linked immunosorbent assay (ELISA) kits.

Change=(Week 12 Level - Baseline Level)

Baseline and Week 12
Change from Baseline in Biomarkers at Week 6
Délai: Baseline and Week 6

Volume-corrected serum concentration (mg/dL) of myokines, bone markers, pro-inflammatory markers, biomarkers of oxidative stress will be measured using enzyme-linked immunosorbent assay (ELISA) kits.

Change=(Week 6 Level - Baseline Level)

Baseline and Week 6
Change from Baseline in Motor Function at Week 12
Délai: Baseline and Week 12

Fugl-Meyer Motor Assessment (FMA) will be used to assess the degree of motor recovery of the hemiparetic upper (range: 0-66) and lower limbs (range: 0-34). Higher scores are indicative of better motor recovery. Short Physical Performance Battery (SPPB) will be used to assess the physical performance, including 5-times sit-to-stand, balance tests (side-by-side-stand, semi-tandem stand, and tandem stand), and gait speed.

Change=(Week 12 Score- Baseline Score)

Baseline and Week 12
Change from Baseline in Motor Function at Week 24
Délai: Baseline and Week 24

Fugl-Meyer Motor Assessment (FMA) will be used to assess the degree of motor recovery of the hemiparetic upper (range: 0-66) and lower limbs (range: 0-34). Higher scores are indicative of better motor recovery. Short Physical Performance Battery (SPPB) will be used to assess the physical performance, including 5-times sit-to-stand, balance tests (side-by-side-stand, semi-tandem stand, and tandem stand), and gait speed.

Change=(Week 24 Score- Baseline Score)

Baseline and Week 24
Change from Baseline in Motor Function (meters) at Week 12
Délai: Baseline and Week 12

The 6-minute walk test (6MWT) will be used to measure walking endurance and capacity. The total distance walked in meters during the test will be recorded.

Change=(Week 12 distance - Baseline distance)

Baseline and Week 12
Change from Baseline in Motor Function (meters) at Week 24
Délai: Baseline and Week 24

The 6-minute walk test (6MWT) will be used to measure walking endurance and capacity. The total distance walked in meters during the test will be recorded.

Change=(Week 24 distance - Baseline distance)

Baseline and Week 24
Change from Baseline in Balance Function at Week 12
Délai: Baseline and Week 12

Balance performance will be assessed using the Mini Balance Evaluation Systems Test (range: 0-28). Higher scores are indicative of better balance performance. Fear of falling will be assessed using the Chinese version of the Activities-Specific Balance Confidence Scale (range: 0-100). Higher scores are indicative of higher balance confidence.

Change=(Week 12 Score- Baseline Score)

Baseline and Week 12
Change from Baseline in Balance Function at Week 24
Délai: Baseline and Week 24

Balance performance will be assessed using the Mini Balance Evaluation Systems Test (range: 0-28). Higher scores are indicative of better balance performance. Fear of falling will be assessed using the Chinese version of the Activities-Specific Balance Confidence Scale (range: 0-100). Higher scores are indicative of higher balance confidence.

Change=(Week 24 Score- Baseline Score)

Baseline and Week 24
Change from Baseline in Cardiopulmonary Response at Week 12
Délai: Baseline and Week 12

Peak oxygen uptake (VO2peak) will be measured using a graded exercise test (GXT). The GXT will be conducted following a well-validated protocol that on a whole-body recumbent stepper to assess cardiopulmonary function in stroke patients.

Change=(Week 12 VO2peak - Baseline VO2peak)

Baseline and Week 12
Change from Baseline in Cardiopulmonary Response at Week 24
Délai: Baseline and Week 24

Peak oxygen uptake (VO2peak) will be measured using a graded exercise test (GXT). The GXT will be conducted following a well-validated protocol that on a whole-body recumbent stepper to assess cardiopulmonary function in stroke patients.

Change=(Week 24 VO2peak - Baseline VO2peak)

Baseline and Week 24
Change from Baseline in Psychosocial Responses at Week 12
Délai: Baseline and Week 12

Post-stroke fatigue will be assessed using the Fatigue Severity Scale (range: 1-7). Higher scores are indicative of more severe fatigue.

Health-related quality of life will be assessed using 12-Item Short Form Health Survey (range: 0-100). Higher scores are indicative of better quality of life.

Exercise enjoyment will be assessed by the Physical Activity Enjoyment Scale and Behavioural Regulation Exercise Questionnaire-3 (range: 0-400). Higher scores indicate a higher exercise enjoyment level.

Motivation for exercise will be assessed using the Behavioural Regulation Exercise Questionnaire-3 (range: 0-96). Higher scores indicate more motivation to exercise. A semi-structured interview will be additionally conducted at the end of the intervention (week 12) to explore the experiences of HIIT in stroke patients.

Change=(Week 12 Score - Baseline Score)

Baseline and Week 12
Change from Baseline in Psychosocial Responses at Week 24
Délai: Baseline and Week 24

Post-stroke fatigue will be assessed using the Fatigue Severity Scale (range: 1-7). Higher scores are indicative of more severe fatigue.

Health-related quality of life will be assessed using 12-Item Short Form Health Survey (range: 0-100). Higher scores are indicative of better quality of life.

Exercise enjoyment will be assessed by the Physical Activity Enjoyment Scale and Behavioural Regulation Exercise Questionnaire-3 (range: 0-400). Higher scores indicate a higher exercise enjoyment level.

Motivation for exercise will be assessed using the Behavioural Regulation Exercise Questionnaire-3 (range: 0-96). Higher scores indicate more motivation to exercise. A semi-structured interview will be additionally conducted at the end of the intervention (week 12) to explore the experiences of HIIT in stroke patients.

Change=(Week 24 Score - Baseline Score)

Baseline and Week 24

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 août 2024

Achèvement primaire (Estimé)

5 août 2027

Achèvement de l'étude (Estimé)

5 août 2027

Dates d'inscription aux études

Première soumission

30 juillet 2024

Première soumission répondant aux critères de contrôle qualité

14 août 2024

Première publication (Réel)

15 août 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

21 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 septembre 2026

Dernière vérification

1 septembre 2025

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner